OakChart

Theriva Biologics Inc

TOVXHealthcare·Biotechnology·USA·Nano·AMEX·Nov 11 • 11:13 AM ET

0.1589+0.0047 (3.05%)
2026-11-11 17:14 CET
Market cap
7.08 USD m
Revenue, TTM
0.30 USD m
Net income, TTM
-13.13 USD m
Free cash flow, TTM
-12.76 USD m
EPS diluted, TTM
-0.67
P/E
-
Compare

Price

TOVX against its 20, 50 and 200-day averages
2050200miss
0.200.300.40145.0M290.1MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TOVXclose 0.1620-day 0.1950-day 0.21200-day 0.240.1652w low

67.7% under the 52-week high of 0.49 on 20 Apr 2026. 52-week low 0.14 on 2 Nov 2026. Last 15 sessions, 50.0% high to low

Profile

TOVX
52-week range, 5% of the way up
0.140.49

Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients. SYN-004 is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer on January 8, 2001 and is headquartered in Rockville, MD.

Employees16
IPOApr 05, 1993
Beta1.26
ATR, 14d0.02
Rel volume0.50
Short float3.13%
Insider own1.63%
Inst own4.36%

Snapshot

6 groups

Valuation

Index-
Market Cap7.30M
Enterprise Value-0.49M
Income-13.13M
Sales0.30M
Book/sh0.27
Cash/sh0.25
Dividend Est.-
Dividend TTM-
Dividend Ex-DateDec 27, 2007
Dividend Gr. 3/5Y- -
Payout-
Employees16
IPOApr 05, 1993

Ratios

P/E-
Forward P/E-
PEG-
P/S24.32
P/B0.60
P/C0.64
P/FCF-
EV/EBITDA-
EV/Sales-1.65
Quick Ratio1.13
Current Ratio1.13
Debt/Eq0.29
LT Debt/Eq0.25
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.67
EPS next Y-0.20
EPS next Q-0.06
EPS this Y87.98%
EPS next Y20.00%
EPS next 5Y-
EPS past 3/5Y60.07% 58.31%
Sales past 3/5Y- -
EPS Y/Y TTM94.38%
Sales Y/Y TTM-
EPS Q/Q96.37%
Sales Q/Q-
EarningsAug 11 BMO
EPS/Sales Surpr.-27.27% -

Ownership

Insider Own1.63%
Insider Trans0.00%
Inst Own4.36%
Inst Trans0.22%
ROA-32.87%
ROE-101.87%
ROIC-76.53%
Gross Margin65.67%
Oper. Margin-4224.33%
Profit Margin-4376.00%
SMA20-14.43%
SMA50-25.30%
SMA200-33.31%
Trades-

Technical

Shs Outstand45.89M
Shs Float45.14M
Short Float3.13%
Short Ratio0.71
Short Interest1.41M
52W High0.49 -67.70%
52W Low0.14 16.84%
Volatility14.86% 9.86%
ATR (14)0.02
RSI (14)32.00
Beta1.26
Rel Volume0.50
Avg Volume1.98M
Volume300,734

Performance

Perf Week-16.37%
Perf Month-26.33%
Perf Quarter-30.91%
Perf Half Y-51.85%
Perf YTD-24.48%
Perf Year-42.39%
Perf 3Y-98.65%
Perf 5Y-99.84%
Perf 10Y-100.00%
Recom1.00
Target Price4.00
Prev Close0.15
Price0.16
Change %3.05%

Peers

Mkt cap
TickerCompanyMkt cap
CLDICalidi Biotherapeutics Inc2.53M
ONCYOncolytics Biotech Inc50.36M
CADLCandel Therapeutics Inc724.64M
GNLXGenelux Corp89.36M
ACXPAcurx Pharmaceuticals Inc5.95M
MCRBSeres Therapeutics Inc14.78M
REPLReplimune Group Inc2.15B
ELTXElicio Therapeutics Inc43.59M
IMRXImmuneering Corp252.58M
SLXNSilexion Therapeutics Corp1.93M

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 206
  • Theriva Biologics Announces Sale of SYN-004 (ribaxamase) and Related Antibiotic-Degrading Enzyme Portfolio to Biossil Labs Inc. (GlobeNewswire) +7.92%
  • Theriva Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine (GlobeNewswire) +7.14%
  • Theriva Biologics: Q2 Earnings Snapshot (Associated Press)
  • Theriva Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results (GlobeNewswire)
  • Theriva Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire)
  • Loading…
  • Theriva Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire) -7.07%
  • Theriva Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research (GlobeNewswire) +26.08%
  • Theriva Biologics: Q1 Earnings Snapshot (Associated Press)
  • Theriva Biologics Reports First Quarter 2026 Operational Highlights and Financial Results (GlobeNewswire)
  • Theriva Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting (GlobeNewswire) +59.41%
  • Theriva Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire) +8.42%
  • Theriva Biologics Reports Full-Year 2025 Operational Highlights and Financial Results (GlobeNewswire)
  • Theriva Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications (GlobeNewswire) +6.25%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-11-0.070-0.055-0.0700.30-2
2026Q12026-05-05-0.050-0.050-0.0500.30-2
2025Q42026-03-121.850-0.435-0.098--2
2025Q32025-11-12-0.450-0.380-0.451--1
2025Q22025-08-11-1.930-0.775-1.934--2
2025Q12025-05-14-1.550-4.190-1.554--1
2024Q42025-03-066.030-7.220-1.598--1
2024Q32024-11-12-6.810-6.250-6.811--2
2024Q22024-08-13-10.750--10.720---
2024Q12024-05-07-7.500-4.750-7.530--1
2023Q42024-03-25-7.750-10.250-7.997--2
2023Q32023-11-13-4.750-10.500-4.845--1
2023Q22023-08-08-8.500-9.000-8.381--2
2023Q12023-05-11-7.500-8.875-7.402--2
2022Q42023-03-30-9.250-8.375-8.8860.000.002
2022Q32022-11-10-8.250-9.250-8.1940.000.002

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-245-257.5-244.49--
2020FY-165--165.13--
2021FY-47.500-35.000-47.568--
2022FY-32.750-31.875-32.662--
2023FY-28.500-32.125-28.480--
2024FY-19.030-24.110-19.029--
2025FY-2.080-2.920-2.0800.00-
2026FY--0.250--0.30
2027FY--0.200--0.00
2028FY--0.320--0.00
2029FY--0.380---
2030FY--0.440---

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3R2026-10-28100-0.06-0.06-0.06
2026Q3R2026-10-25200-0.07-0.07-0.06
2026Q3R2026-08-11201-0.07-0.07-0.06
2026Q3R2026-07-20200-0.06-0.07-0.05
2026Q3R2026-05-26201-0.06-0.07-0.05
2026Q3R2026-05-06211-0.06-0.07-0.05
2026Q3R2026-03-30220-0.06-0.06-0.05
2026Q3R2026-03-23210-0.32-0.58-0.05
2026Q3R2026-03-12110-0.05-0.05-0.05
2026Q3R2026-02-25200-0.37-0.58-0.16
2026Q3R2025-11-19100-0.58-0.58-0.58
2026Q3R2025-11-13200-0.37-0.58-0.16
2026Q3R2025-11-12100-0.16-0.16-0.16
2026Q3R2025-11-11100-0.16-0.16-0.16

Estimate history

EPS, annual-1575-1014.49-244.493-165.125-47.568-32.662-28.48-19.029-2.08-0.6688
Period201720182019202020212022202320242025TTM
EPS, quarterly-10.72-6.811-1.598-1.554-1.934-0.451-0.098-0.05-0.07
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000.3
Period201720182019202020212022202320242025TTM
Sales, quarterly00000000.30
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.0150.0620.0670.1170.5280.6050.6862.78235.68845.893
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.8962.6172.7822.7829.05910.30535.68845.89345.893
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.300.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.100.110.140.140.270.090.200.240.27
Gross Profit0.20-0.11-0.14-0.14-0.27-0.09-0.20-0.24-0.27
Selling, General and Administrative Excl. Other12.8714.9118.5921.9619.0214.199.9615.4217.30
Research and Development5.318.6012.0314.3111.727.805.1311.0811.84
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-12.67-15.02-18.73-22.09-19.29-14.27-10.16-15.66-17.57
Interest Expense-----0.000.000.000.00
Unusual Expense-0.759.037.62-0.662.290.000.00--4.08
Net Income Before Taxes-11.62-23.74-25.65-19.99-21.11-14.27-10.12-15.38-13.42
Income Taxes0.000.000.00-1.64-1.430.000.000.000.00
Consolidated Net Income-11.62-23.74-25.65-18.35-20.02-14.27-10.12-15.38-13.42
Net Income From Continuing Operations-11.62-23.74-25.65-18.35-20.02-14.27-10.04-15.30-13.37
Net Income-13.13-25.25-25.65-18.35-20.02-23.19-12.56-16.08-25.29
EPS (Recurring)-0.30-1.56-15.07-29.20-30.05-47.57-165.12-244.49-1,129.14
EPS (Basic, Before Extraordinaries)-0.67-2.08-19.03-28.48-32.66-47.57-165.12-244.49-1,014.49
EPS (Diluted)-0.67-2.08-19.03-28.48-32.66-47.57-165.12-244.49-1,014.49
EBITDA-12.57-14.91-18.59-21.96-19.02-14.19-9.96-15.42-17.30
Non-Operating Income (Expense)0.310.310.691.440.470.010.040.280.07
Other After Tax Adjustments0.000.000.000.00-0.340.000.000.000.00
Stock Option Compensation Expense0.590.660.670.440.260.200.350.262.07
Price To Sales Ratio38.27--------
Gross Margin65.67--------
Operating Margin-4,224.33--------
Net Margin-4,376.00--------
Shares Outstanding45.8935.692.780.690.600.530.120.070.06
Market Capitalization7.087.084.877.337.2135.9411.208.528.67

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.300.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.020.020.030.030.030.030.030.03
Gross Profit-0.020.28-0.03-0.03-0.03-0.03-0.03-0.03
Selling, General and Administrative Excl. Other3.272.382.814.413.954.374.375.00
Research and Development1.270.351.132.551.952.972.892.73
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-3.29-2.10-2.84-4.44-3.98-4.40-4.39-5.04
Unusual Expense0.000.03-0.780.009.150.020.182.85
Net Income Before Taxes-3.22-2.04-2.00-4.36-13.06-4.32-4.45-7.73
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-3.22-2.04-2.00-4.36-13.06-4.32-4.45-7.73
Net Income From Continuing Operations-3.22-2.04-2.00-4.36-13.06-4.32-4.45-7.73
Net Income-3.22-2.04-3.51-4.36-13.06-4.32-4.45-7.73
EPS (Recurring)-0.07-0.05-0.11-0.45-0.98-1.55-1.55-5.05
EPS (Basic, Before Extraordinaries)-0.07-0.05-0.10-0.45-1.93-1.55-1.60-6.81
EPS (Diluted)-0.07-0.05-0.10-0.45-1.93-1.55-1.60-6.81
EBITDA-3.27-2.08-2.81-4.41-3.95-4.37-4.37-5.00
Non-Operating Income (Expense)0.080.080.070.080.070.090.130.16
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.110.140.160.180.140.080.160.12
Price To Sales Ratio38.2726.81------
Gross Margin-92.00------
Operating Margin--700.00------
Net Margin--681.33------
Shares Outstanding45.8945.8935.6910.309.062.782.782.62
Market Capitalization7.088.997.123.893.933.064.871.87

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments13.0611.6123.1841.7967.336.2315.0428.9217.12
Short Term Receivables3.833.321.940.230.000.470.000.000.05
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.581.352.293.501.531.241.380.590.78
Total Current Assets17.4716.2827.4045.5268.867.9316.4329.5117.94
Net Property, Plant & Equipment1.021.542.181.541.480.450.790.610.87
Total Investments and Advances0.050.100.100.100.000.000.000.000.00
Intangible Assets19.6217.3625.4524.68-----
Deferred Tax Assets5.454.384.993.17-----
Other Assets0.080.070.080.020.020.020.020.020.02
Total Assets43.6939.7460.2175.0370.368.4117.2330.1418.84
Short Term Debt Incl. Current Port. of LT Debt0.610.600.550.270.120.290.250.000.00
Accounts Payable1.010.860.770.920.520.892.311.032.02
Other Current Liabilities8.396.135.425.872.911.792.712.357.77
Total Current Liabilities10.017.586.747.063.552.975.283.389.79
Long Term Debt2.020.961.601.411.400.190.470.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities5.454.384.994.79-----
Other Liabilities10.827.747.187.210.000.000.000.300.40
Total Liabilities28.3020.6720.5120.474.963.155.753.6910.20
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.002.732.730.0015.2817.3018.0612.05
Common Equity15.3819.0736.9651.8365.41-7.24-2.9411.31-1.50
Total Shareholders Equity15.3819.0739.7054.5665.418.0314.3729.3610.56
Accumulated Minority Interest0.000.000.000.000.00-2.77-2.88-2.91-1.91
Total Equity15.3819.0739.7054.5665.415.2611.4926.458.64
Total Liabilities & Stockholders Equity43.6939.7460.2175.0370.368.4117.2330.1418.84
Book Value Per Share0.436.8553.8985.67123.84-61.91-43.73182.60-101.81
Tangible Book Value Per Share-0.120.6116.7844.89123.84-61.91-43.73182.60-101.81
Full-Time Employees162222211610111325
Price to Book Ratio0.580.190.180.130.55-1.55-2.900.77-13.64
Return on Assets-56.91-51.33-27.14-27.55-36.22-78.32-64.60-54.58-73.42
Return on Equity-137.82-87.31-38.93-33.38-38.85-89.69-69.99-66.97-210.72
Return on Invested Capital-136.38-128.06-44.43-35.78-21.35-122.22-103.13-45.52-143.73
Quick Ratio1.742.154.076.4519.372.673.118.721.83
Current Ratio1.742.154.076.4519.372.673.118.721.83

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-11.62-23.74-25.65-18.35-19.68-14.27-10.12-15.38-13.42
Depreciation0.100.110.140.140.270.090.200.240.27
Other Funds (Non Cash)1.5110.027.85-1.452.570.420.530.41-1.94
Funds from Operations-10.83-13.61-17.66-21.30-18.28-13.77-9.39-14.73-15.09
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.91-3.060.732.31-0.810.88-2.780.85-2.19
Cash from Operating Activities-12.74-16.67-16.94-19.00-19.08-12.89-12.17-13.87-17.28
Capital Expenditures-0.02-0.04-0.00-0.20-0.12-0.01-0.010.00-0.01
Net Assets From Acquisitions0.000.000.000.00-3.860.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments0.000.000.000.00-0.420.000.000.000.00
Purchase of Investments0.000.000.000.00-0.420.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.02-0.04-0.00-0.20-4.40-0.01-0.010.00-0.01
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock9.1413.535.562.222.4574.003.360.0029.09
Repurchase of Common Pref Stock0.000.000.000.00-0.290.000.000.000.00
Sale of Common Pref Stock9.1413.535.562.222.7374.003.360.0029.09
Proceedsfrom Stock Options2.456.833.602.222.730.003.360.0029.09
Issuance or Reduction of Debt, Net-0.011.44-0.07-0.07-1.380.000.000.000.00
Change in Long Term Debt-0.011.44-0.07-0.07-1.380.000.000.000.00
Issuance of Long Term Debt0.051.510.000.000.000.000.000.000.00
Reduction of Long Term Debt-0.06-0.07-0.07-0.07-1.380.000.000.000.00
Net Financing Active Other Cash Flow3.043.230.00-1.52-3.000.000.000.000.00
Other Financing Activities Uses-1.00-1.000.00-1.52-3.000.000.000.000.00
Cash from Financing Activities12.1618.195.500.62-1.9374.003.360.0029.09
Exchange Rate Effect-0.18-0.09-0.13-0.03-0.03----
Net Change in Cash-0.791.40-11.57-18.61-25.4461.10-8.82-13.8711.80
Free Cash Flow-12.76-16.70-16.94-19.20-19.20-12.90-12.18-13.87-17.29
Preferred Dividends (Cash Flow)--0.000.000.00----
Deferred Taxes & Investment Tax Credit-0.000.00-1.64-1.430.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments11.3414.4313.067.5312.1210.01
Short Term Receivables1.811.793.831.821.771.70
Inventories0.000.000.000.000.000.00
Other Current Assets0.530.540.580.550.850.77
Total Current Assets13.6716.7617.479.9014.7412.48
Net Property, Plant & Equipment2.002.141.021.191.331.42
Total Investments and Advances0.040.040.050.050.050.10
Intangible Assets19.0619.2319.6219.6119.6218.08
Deferred Tax Assets--5.45---
Other Assets0.080.080.080.080.080.08
Total Assets34.8638.2543.6930.8435.8332.16
Short Term Debt Incl. Current Port. of LT Debt0.560.550.610.680.670.62
Accounts Payable0.980.611.010.800.610.44
Other Current Liabilities10.579.118.399.5311.127.09
Total Current Liabilities12.1110.2610.0111.0012.398.15
Long Term Debt2.993.152.022.092.222.24
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--5.45---
Other Liabilities7.579.4410.8211.0110.596.28
Total Liabilities22.6722.8528.3024.1025.2116.66
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity12.1915.4015.386.7410.6215.50
Total Shareholders Equity12.1915.4015.386.7410.6215.50
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity12.1915.4015.386.7410.6215.50
Total Liabilities & Stockholders Equity34.8638.2543.6930.8435.8332.16
Book Value Per Share0.270.340.430.651.175.57
Tangible Book Value Per Share-0.15-0.08-0.12-1.25-0.99-0.93
Full-Time Employees--16---
Price to Book Ratio0.580.580.320.350.080.16
Return on Assets-32.87-60.96-56.91-73.83-75.57-61.35
Return on Equity-101.87-138.91-137.82-166.96-154.46-100.01
Return on Invested Capital-21.19-11.02-11.47-49.42-101.65-24.38
Quick Ratio1.131.631.740.901.191.53
Current Ratio1.131.631.740.901.191.53

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-3.22-2.04-2.00-4.36-13.06-4.32
Depreciation0.020.020.030.030.030.03
Other Funds (Non Cash)0.030.300.640.549.01-0.17
Funds from Operations-3.57-2.13-1.33-3.79-4.02-4.47
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.49-0.32-1.55-0.53-0.69-0.29
Cash from Operating Activities-3.08-2.46-2.88-4.32-4.71-4.76
Capital Expenditures-0.000.000.00-0.02-0.020.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.000.000.00-0.02-0.020.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.00-0.000.000.00
Change in Capital Stock0.002.306.550.286.690.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.002.306.550.286.690.00
Proceedsfrom Stock Options0.002.30-0.140.286.690.00
Issuance or Reduction of Debt, Net-0.01-0.050.010.030.051.34
Change in Long Term Debt-0.01-0.050.010.030.051.34
Issuance of Long Term Debt0.000.000.010.030.061.40
Reduction of Long Term Debt-0.01-0.05-0.00-0.00-0.01-0.06
Net Financing Active Other Cash Flow-0.001.611.89-0.460.071.73
Other Financing Activities Uses0.000.00-0.50-0.500.000.00
Cash from Financing Activities-0.013.878.46-0.156.813.07
Exchange Rate Effect0.01-0.04-0.05-0.11-0.030.09
Net Change in Cash-3.101.375.53-4.592.05-1.59
Free Cash Flow-3.09-2.46-2.88-4.34-4.73-4.76

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.13%1.4M45.1M523.10K
2026-10-154.09%1.8M45.1M518.97K
2026-09-303.79%1.7M45.1M1.13M
2026-09-153.52%1.6M45.1M1.24M
2026-08-313.91%1.8M45.1M6.01M
2026-08-143.80%1.7M45.1M6.28M
2026-07-314.69%2.1M45.1M6.68M
2026-07-155.18%2.3M45.1M20.84M
2026-06-303.22%1.5M45.1M20.68M
2026-06-156.56%3.0M45.1M25.36M
2026-05-296.03%2.7M45.1M21.07M
2026-05-158.99%4.1M45.1M25.93M
2026-04-3018.85%8.5M45.1M26.12M
2026-04-155.64%2.5M45.1M12.55M
2026-03-3115.28%6.9M44.9M12.33M
2026-03-1312.19%5.5M44.9M9.90M
2026-02-2717.52%6.1M34.9M9.99M
2026-02-1316.14%5.6M34.9M5.16M
2026-01-3021.77%7.6M34.9M5.29M
2026-01-1516.71%5.8M34.9M15.42M

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-028-KCurrent report2026-10-30SEC
2026-10-20DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-11-18SEC
2026-10-09PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-09SEC
2026-08-24S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-048-KCurrent report2026-08-03SEC
2026-07-078-KCurrent report2026-07-07SEC
2026-06-29ARSAnnual report to security holders. 2025-12-31SEC
2026-06-29DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-08-03SEC
2026-06-18PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-18SEC
2026-06-118-KCurrent report2026-06-11SEC
2026-06-058-KCurrent report2026-06-05SEC
2026-05-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-058-KCurrent report2026-05-05SEC
2026-04-30DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-05SEC
2026-04-20PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-20SEC
2026-04-178-KCurrent report2026-04-17SEC
2026-04-098-KCurrent report2026-04-09SEC
2026-03-238-KCurrent report2026-03-23SEC
2026-03-16DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-09SEC
2026-03-1210-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-128-KCurrent report2026-03-12SEC
2026-03-04PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-03-04SEC
2026-02-188-KCurrent report2026-02-17SEC
2026-02-128-KCurrent report2026-02-11SEC
2026-01-128-KCurrent report2026-01-12SEC
2026-01-064Statement of changes in beneficial ownership of securities2026-01-05SEC
2026-01-064Statement of changes in beneficial ownership of securities2026-01-05SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC1.06%
JANE STREET GROUP, LLC0.72%
GEODE CAPITAL MANAGEMENT, LLC0.65%
VANGUARD FIDUCIARY TRUST CO0.53%
Ikarian Capital, LLC0.24%
Virtu Financial LLC0.19%
NORTHERN TRUST CORP0.18%
RENAISSANCE TECHNOLOGIES LLC0.14%
XTX Topco Ltd0.12%
StoneX Group Inc.0.07%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND1.06%
Fidelity Extended Market Index Fund0.54%
Fidelity Series Total Market Index Fund0.06%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. TOVX. Cached 15 minutes.

Some panels did not load: ratings, insider.